GleamWall
中文EN

TECX Tectonic Therapeutic, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1681087 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-72.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-35.5%
ROA-33.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio19.71x
Interest coverage-3,216.43x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$17.44M$18.05M$20.87M$16.34M$16.93M$17.18M$13.04M$9.16M
SG&A expense$6.01M$6.17M$6.43M$5.17M$4.96M$5.15M$5.26M$6.75M
Operating income-$23.46M-$24.22M-$27.30M-$21.52M-$21.89M-$22.33M-$18.30M-$13.99M
Interest expense$4,000$6,000$8,000$12,000$14,000$17,000$20,000$22,000
Pretax income-$21.35M-$22.21M—-$18.97M-$19.04M-$19.01M—-$12.37M
Income tax$0$77,000—$254,000$0$976,000—$0
Net income-$21.35M-$22.29M-$25.24M-$19.23M-$19.04M-$19.98M-$15.91M-$12.37M
EBITDA-$23.21M-$23.93M-$27.00M-$21.18M-$21.55M-$21.99M-$17.94M-$13.48M
EPS (basic)-1.08-1.18-1.34—-1.02-1.07-0.93—
EPS (diluted)-1.08-1.18-1.34—-1.02-1.07-0.93—
Dividends declared per share———0.000.000.000.000.00
Weighted avg. shares (diluted)19.70M18.96M18.77M—18.71M18.68M17.16M—
Balance sheet
Cash & equivalents$234.67M$227.07M$236.89M$253.80M$268.44M$287.38M$306.25M$141.83M
Current assets$238.55M$231.10M$239.89M$257.36M$273.24M$290.85M$309.64M$146.86M
PP&E, net$793,000$858,000$1.02M$1.19M$1.41M$1.68M$1.92M$2.15M
Total assets$243.86M$237.03M$246.58M$261.04M$277.00M$295.31M$314.83M$152.91M
Current liabilities$12.10M$10.37M$12.96M$9.67M$9.37M$11.36M$13.51M$11.61M
Total liabilities$14.54M$13.19M$16.16M$9.71M$9.47M$11.55M$13.79M$12.13M
Shareholders' equity$229.32M$223.85M$230.42M$251.33M$267.53M$283.77M$301.04M$140.78M
Shares outstanding19.94M19.24M18.83M18.74M18.71M18.71M18.67M14.86M
Cash flow statement
Operating cash flow-$14.91M-$21.45M-$18.41M-$14.46M-$17.82M-$14.72M-$13.08M-$16.82M
Capital expenditure$0$79,000$19,000$0$181,000$0$27,000$3,000
Free cash flow-$14.91M-$21.53M-$18.43M-$14.46M-$18.00M-$14.72M-$13.11M-$16.82M
Investing cash flow$0-$59,000-$19,000$0-$166,000$55,000-$27,000-$3,000
Financing cash flow$22.50M$11.68M$847,000-$141,000-$457,000-$4.17M$178.12M-$1.07M
Depreciation & amortization$250,000$285,000$304,000$333,000$342,000$340,000$360,000$508,000
Stock-based compensation$4.24M$4.01M$3.21M$2.99M$2.82M$2.59M$2.10M$1.12M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.